<DOC>
	<DOCNO>NCT01529710</DOCNO>
	<brief_summary>Clinical Trial Phase : Phase III Primary Objectives : - Compare Mirazid Praziquantel cure rate Schistosoma specie . - Compare Mirazid Praziquantel effect lower intensity infection Schistosoma specie . Secondary Objective : Identify compare type severity side adverse effect Mirazid Praziquantel . Study Population:200 Schistosomiasis infect person type Schistosomiasis age 15-35 year . Those subject select among screened.Subjects include gender exclude chronically ill chronic liver disease patient types Schistosomiasis . Recruitment Period:3 month subject follow another 3 month follow 3 month statistical analysis report write Study Duration : Total study duration expect 9 month : 3 month recruitment , 3 month follow 3 month data management report write . Endpoints : Will measure 3 month successful administration treatment either Mirazid Praziquantel per randomization scheme . By , final assessment response treatment do examine urine stool subject presence Schistosoma egg density find . Three negative urine stool sample collect 2-days apart 12 week post treatment indicate treatment success . One positive sample collect week 12 indicate infection Schistosomiasis .</brief_summary>
	<brief_title>Safety Efficacy Mirazid Schistosomiasis Treatment</brief_title>
	<detailed_description>Study Design : This phase III , open-label randomize non-placebo-controlled Study investigator compare efficacy safety Mirazid Praziquantel treatment Schistosomiasis . After screen , positive subject one Schistosomiasis recruit study . They treat Mirazid 600 mg oral ( Soft Gelatin Capsules ) 6 consecutive day 40mg/Kg body weight Praziquantel single oral dose . Subjects evaluate success treatment 12 week treatment . Evaluation do examine urine stool sample Schistosomiasis include egg count positive case .</detailed_description>
	<mesh_term>Schistosomiasis</mesh_term>
	<mesh_term>Schistosomiasis mansoni</mesh_term>
	<mesh_term>Schistosomiasis haematobia</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Adolescent young adult age 1530 year Positive Schistosoma infection type . Mixed Schistosoma infection type History administration treatment Schistosoma infection last 6 month prior study . Severely ill patient Advanced chronic liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Schistosomiasis hematobium</keyword>
	<keyword>Schistosomiasis mansoni</keyword>
</DOC>